Overexpression of Galgt2 Reduces Dystrophic Pathology in the Skeletal Muscles of Alpha Sarcoglycan-deficient Mice

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2009 Jun 6

PMID 19498002

Citations 33

Authors

Rui Xu

Sarah DeVries

Marybeth Camboni

Paul T Martin

Affiliations

Soon will be listed here.

Abstract

Recent studies have shown that a number of genes that are not mutated in various forms of muscular dystrophy may serve as surrogates to protect skeletal myofibers from injury. One such gene is Galgt2, which is also called cytotoxic T cell GalNAc transferase in mice. In this study, we show that Galgt2 overexpression reduces the development of dystrophic pathology in the skeletal muscles of mice lacking alpha sarcoglycan (Sgca), a mouse model for limb girdle muscular dystrophy 2D. Galgt2 transgenic Sgca(-/-) mice showed reduced levels of myofiber damage, as evidenced by i) normal levels of serum creatine kinase activity, ii) a lack of Evans blue dye uptake into myofibers, iii) normal levels of mouse locomotor activity, and iv) near normal percentages of myofibers with centrally located nuclei. In addition, the overexpression of Galgt2 in the early postnatal period using an adeno-associated virus gene therapy vector protected Sgca(-/-) myofibers from damage, as observed using histopathology measurements. Galgt2 transgenic Sgca(-/-) mice also had increased levels of glycosylation of alpha dystroglycan with the CT carbohydrate, but showed no up-regulation of beta, gamma, delta, or epsilon sarcoglycan. These data, coupled with results from our previous studies, show that Galgt2 has therapeutic effects in three distinct forms of muscular dystrophy and may, therefore, have a broad spectrum of therapeutic potential for the treatment of various myopathies.

Citing Articles

-Glycan on the Non-Consensus N-X-C Glycosylation Site Impacts Activity, Stability, and Localization of the Sd Synthase B4GALNT2.

Cogez V, Vicogne D, Schulz C, Portier L, Venturi G, de Ruyck J Int J Mol Sci. 2023; 24(4).

PMID: 36835549 PMC: 9959560. DOI: 10.3390/ijms24044139.

Current Strategies of Muscular Dystrophy Therapeutics: An Overview.

Lim K, Yokota T Methods Mol Biol. 2022; 2587:3-30.

PMID: 36401021 DOI: 10.1007/978-1-0716-2772-3_1.

The story of the Sd antigen and of its cognate enzyme B4GALNT2: What is new?.

Duca M, Malagolini N, DallOlio F Glycoconj J. 2022; 40(1):123-133.

PMID: 36287346 DOI: 10.1007/s10719-022-10089-1.

A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.

Flanigan K, Vetter T, Simmons T, Iammarino M, Frair E, Rinaldi F Mol Ther Methods Clin Dev. 2022; 27:47-60.

PMID: 36186954 PMC: 9483573. DOI: 10.1016/j.omtm.2022.08.009.

Current Pharmacological Strategies for Duchenne Muscular Dystrophy.

Yao S, Chen Z, Yu Y, Zhang N, Jiang H, Zhang G Front Cell Dev Biol. 2021; 9:689533.

PMID: 34490244 PMC: 8417245. DOI: 10.3389/fcell.2021.689533.

References

Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, DAntona G, Pellegrino M . Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science. 2003; 301(5632):487-92. DOI: 10.1126/science.1082254. View

Xu H, Wu X, Wewer U, Engvall E . Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. Nat Genet. 1994; 8(3):297-302. DOI: 10.1038/ng1194-297. View

Xia B, Hoyte K, Kammesheidt A, Deerinck T, Ellisman M, Martin P . Overexpression of the CT GalNAc transferase in skeletal muscle alters myofiber growth, neuromuscular structure, and laminin expression. Dev Biol. 2002; 242(1):58-73. DOI: 10.1006/dbio.2001.0530. View

Pacak C, Walter G, Gaidosh G, Bryant N, Lewis M, Germain S . Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol Ther. 2007; 15(10):1775-81. DOI: 10.1038/sj.mt.6300246. View

Milner D, Kaufman S . Alpha7beta1 integrin does not alleviate disease in a mouse model of limb girdle muscular dystrophy type 2F. Am J Pathol. 2007; 170(2):609-19. PMC: 1851849. DOI: 10.2353/ajpath.2007.060686. View

Roberds S, Leturcq F, Allamand V, Piccolo F, Jeanpierre M, Anderson R . Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell. 1994; 78(4):625-33. DOI: 10.1016/0092-8674(94)90527-4. View

Hack A, Lam M, Cordier L, Shoturma D, Ly C, Hadhazy M . Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. J Cell Sci. 2000; 113 ( Pt 14):2535-44. DOI: 10.1242/jcs.113.14.2535. View

Moll J, Barzaghi P, Lin S, Bezakova G, Lochmuller H, Engvall E . An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature. 2001; 413(6853):302-7. DOI: 10.1038/35095054. View

Xiao X, Li J, Samulski R . Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998; 72(3):2224-32. PMC: 109519. DOI: 10.1128/JVI.72.3.2224-2232.1998. View

10.

Jayasinha V, Nguyen H, Xia B, Kammesheidt A, Hoyte K, Martin P . Inhibition of dystroglycan cleavage causes muscular dystrophy in transgenic mice. Neuromuscul Disord. 2003; 13(5):365-75. DOI: 10.1016/s0960-8966(03)00040-3. View

11.

Krag T, Bogdanovich S, Jensen C, Fischer M, Hansen-Schwartz J, Javazon E . Heregulin ameliorates the dystrophic phenotype in mdx mice. Proc Natl Acad Sci U S A. 2004; 101(38):13856-60. PMC: 518764. DOI: 10.1073/pnas.0405972101. View

12.

Wagner K, McPherron A, Winik N, Lee S . Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol. 2002; 52(6):832-6. DOI: 10.1002/ana.10385. View

13.

Imamura M, Mochizuki Y, Engvall E, Takeda S . Epsilon-sarcoglycan compensates for lack of alpha-sarcoglycan in a mouse model of limb-girdle muscular dystrophy. Hum Mol Genet. 2005; 14(6):775-83. DOI: 10.1093/hmg/ddi072. View

14.

Lefrancois L, Bevan M . Functional modifications of cytotoxic T-lymphocyte T200 glycoprotein recognized by monoclonal antibodies. Nature. 1985; 314(6010):449-52. DOI: 10.1038/314449a0. View

15.

Ervasti J, Campbell K . Membrane organization of the dystrophin-glycoprotein complex. Cell. 1991; 66(6):1121-31. DOI: 10.1016/0092-8674(91)90035-w. View

16.

Araishi K, Sasaoka T, Imamura M, Noguchi S, Hama H, Wakabayashi E . Loss of the sarcoglycan complex and sarcospan leads to muscular dystrophy in beta-sarcoglycan-deficient mice. Hum Mol Genet. 1999; 8(9):1589-98. DOI: 10.1093/hmg/8.9.1589. View

17.

Chakkalakal J, Harrison M, Carbonetto S, Chin E, Michel R, Jasmin B . Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. Hum Mol Genet. 2003; 13(4):379-88. DOI: 10.1093/hmg/ddh037. View

18.

Piccolo F, Roberds S, Jeanpierre M, Leturcq F, Azibi K, Beldjord C . Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. Nat Genet. 1995; 10(2):243-5. DOI: 10.1038/ng0695-243. View

19.

Dressman D, Araishi K, Imamura M, Sasaoka T, Liu L, Engvall E . Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity. Hum Gene Ther. 2002; 13(13):1631-46. DOI: 10.1089/10430340260201725. View

20.

Deconinck A, Rafael J, Skinner J, Brown S, Potter A, METZINGER L . Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell. 1997; 90(4):717-27. DOI: 10.1016/s0092-8674(00)80532-2. View